The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine (GX) versus tislelizumab plus gemcitabine/cisplatin (GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter study (PROGRESS).
 
Dongmei Ji
No Relationships to Disclose
 
Yanan Yang
No Relationships to Disclose
 
Wendong Gu
No Relationships to Disclose
 
Shichuan Zhang
No Relationships to Disclose
 
Wenjun Liao
No Relationships to Disclose
 
Binbin Song
No Relationships to Disclose
 
Xiaofang Xu
No Relationships to Disclose
 
Xiaoshen Wang
No Relationships to Disclose
 
Xinchu Ni
No Relationships to Disclose
 
Ximei Zhang
No Relationships to Disclose
 
Xin Liu
No Relationships to Disclose
 
Si Sun
No Relationships to Disclose
 
Youzhou Sang
No Relationships to Disclose
 
Guangliang Chen
No Relationships to Disclose
 
Hongmei Ying
No Relationships to Disclose
 
Chunying Shen
No Relationships to Disclose
 
Xiayun He
No Relationships to Disclose
 
Xueguan Lu
No Relationships to Disclose
 
Chaosu Hu
No Relationships to Disclose
 
Tingting Xu
No Relationships to Disclose